Bortezomib Sensitization of Recurrent Grade-4 Glioma With Unmethylated MGMT Promoter to Temozolomide Phase 1B/II Study
Latest Information Update: 12 Jun 2024
At a glance
- Drugs Bortezomib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms BORTEM-17
- 27 Feb 2024 Planned End Date changed from 30 Aug 2023 to 31 Dec 2025.
- 27 Feb 2024 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2025.
- 06 Jun 2023 Interim analysis results from this trial presented at the 59th Annual Meeting of the American Society of Clinical Oncology